WO2020253415A1 - 2-甲基-1,8-萘啶类化合物及其制备方法与应用 - Google Patents

2-甲基-1,8-萘啶类化合物及其制备方法与应用 Download PDF

Info

Publication number
WO2020253415A1
WO2020253415A1 PCT/CN2020/089428 CN2020089428W WO2020253415A1 WO 2020253415 A1 WO2020253415 A1 WO 2020253415A1 CN 2020089428 W CN2020089428 W CN 2020089428W WO 2020253415 A1 WO2020253415 A1 WO 2020253415A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
naphthyridine
compound
group
preparing
Prior art date
Application number
PCT/CN2020/089428
Other languages
English (en)
French (fr)
Inventor
陈修文
梁婉仪
郑文镳
杨志海
何芊林
李亦彪
Original Assignee
五邑大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 五邑大学 filed Critical 五邑大学
Publication of WO2020253415A1 publication Critical patent/WO2020253415A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to the field of synthesis technology, in particular to 2-methyl-1,8-naphthyridine compounds, as well as its preparation method and application.
  • Naphthyridine nitrogen heterocyclic compounds are a very important type of heterocyclic system, which are common in pharmaceutical intermediates and natural products, and have potential biological activities. Among them, 1,8-naphthyridine is also an important heterocyclic system, which has a wide range of applications in the fields of organic intermediates, medicine, pesticides, and materials science.
  • Methylated drug candidates exhibit unique properties due to changes in solubility, conformation, and metabolic activity.
  • p38a is an inhibitor of MAP3 kinase. After methylation, the potency of p38a is significantly enhanced, and the IC50 is changed from greater than 2500nm to about 12nm.
  • most methods still need to use metal catalysis, and the reaction needs to be realized under high temperature conditions, which has low atom utilization, complex side reactions, and main reaction yields. Disadvantages such as low rate. Therefore, we hope to synthesize 2-methyl-1,8-naphthyridine compounds through a metal-free, room temperature, green, efficient, and simple methylation strategy.
  • the object of the present invention is to provide a 2-methyl-1,8-naphthyridine compound and its preparation method and application.
  • the 2-methyl-1,8-naphthyridine compound of the present invention has a novel structure and high biological activity.
  • the preparation method of the present invention does not need to add a metal catalyst, has mild conditions, is green and environmentally friendly, has high efficiency, simple and safe operation, and the prepared 2-methyl-1,8-naphthyridine compound can be further applied to antitumor drugs.
  • R 1 is selected from the group consisting of phenyl, substituted phenyl, thiazolyl, pyrazinyl, furyl, benzothienyl and 1,3-benzodioxy
  • R 2 is hydrogen or alkyl; or R 1 and R 2 form a ring structure
  • the substituted phenyl group is nitrophenyl, halophenyl, methoxyphenyl or trifluoromethylphenyl;
  • the alkyl group is a C 1-6 alkyl group.
  • the nitrophenyl group is selected from 2-nitrophenyl, 3-nitrophenyl or 4-nitrophenyl; further preferably, the nitrophenyl group is 4-nitrophenyl.
  • the halogenated phenyl group is selected from 2-halophenyl, 3-halophenyl or 4-halophenyl; wherein, the halogen is selected from fluorine, chlorine, bromine or iodine; further preferably, the The halogenated phenyl group is 4-bromophenyl.
  • the methoxyphenyl is selected from 2-methoxyphenyl, 3-methoxyphenyl or 4-methoxyphenyl; further preferably, the methoxyphenyl is 3- Methoxyphenyl.
  • the thiazolyl is selected from thiazol-2-yl, thiazol-4-yl or thiazol-5-yl; further preferably, the thiazolyl is thiazol-2-yl.
  • the pyrazinyl group is selected from pyrazin-2-yl.
  • the trifluoromethyl phenyl group is selected from 2-trifluoromethyl phenyl group, 3-trifluoromethyl phenyl group or 4-trifluoromethyl phenyl group; further preferably, the trifluoromethyl group Phenyl is 4-trifluoromethylphenyl.
  • the furan group is selected from furan-2-yl or furan-3-yl; further preferably, the furan group is furan-2-yl.
  • the benzothienyl group is selected from 2-benzothienyl or 3-benzothienyl; further preferably, the benzothienyl is 2-benzothienyl.
  • the 1,3-benzodioxy group is selected from 1,3-benzodioxy-4-yl or 1,3-benzodiox-5-yl; further preferably, the 1,3- 3-benzodioxy is 1,3-benzodioxy-5-yl.
  • the C 1-6 alkyl group is selected from methyl, ethyl, propyl, butyl, pentyl or hexyl; further preferably, the C 1-6 alkyl group is a methyl group.
  • the R 1 and R 2 form a cyclic structure.
  • the 2-methyl-1,8-naphthyridine compound has the following structure:
  • the above-mentioned preparation method of 2-methyl-1,8-naphthyridine compound includes the following steps:
  • the 1,8-naphthyridine compound, base, alcohol, and methylating reagent are mixed uniformly, and reacted at 80-160°C for 5-24 hours to obtain 2-methyl-1,8-naphthyridine compound.
  • the reaction is carried out in a protective atmosphere; further preferably, the reaction is carried out in a nitrogen atmosphere.
  • the 1,8-naphthyridine compound has a structure shown in formula II:
  • R 1 is selected from the group consisting of phenyl, substituted phenyl, thiazolyl, pyrazinyl, furyl, benzothienyl and 1,3-benzodioxy, and R 2 is hydrogen or alkyl ; Or R 1 and R 2 form a ring structure;
  • the substituted phenyl group is nitrophenyl, halophenyl, methoxyphenyl or trifluoromethylphenyl;
  • the alkyl group is a C 1-6 alkyl group.
  • the nitrophenyl group is selected from 2-nitrophenyl, 3-nitrophenyl or 4-nitrophenyl; further preferably, the nitrophenyl group is 4-nitrophenyl.
  • the halogenated phenyl group is selected from 2-halophenyl, 3-halophenyl or 4-halophenyl; wherein, the halogen is selected from fluorine, chlorine, bromine or iodine; further preferably, the The halogenated phenyl group is 4-bromophenyl.
  • the methoxyphenyl is selected from 2-methoxyphenyl, 3-methoxyphenyl or 4-methoxyphenyl; further preferably, the methoxyphenyl is 3- Methoxyphenyl.
  • the thiazolyl is selected from thiazol-2-yl, thiazol-4-yl or thiazol-5-yl; further preferably, the thiazolyl is thiazol-2-yl.
  • the pyrazinyl group is selected from pyrazin-2-yl.
  • the trifluoromethyl phenyl group is selected from 2-trifluoromethyl phenyl group, 3-trifluoromethyl phenyl group or 4-trifluoromethyl phenyl group; further preferably, the trifluoromethyl group Phenyl is 4-trifluoromethylphenyl.
  • the furan group is selected from furan-2-yl or furan-3-yl; further preferably, the furan group is furan-2-yl.
  • the benzothienyl group is selected from 2-benzothienyl or 3-benzothienyl; further preferably, the benzothienyl is 2-benzothienyl.
  • the 1,3-benzodioxy group is selected from 1,3-benzodioxy-4-yl or 1,3-benzodiox-5-yl; further preferably, the 1,3- 3-benzodioxy is 1,3-benzodioxy-5-yl.
  • the C 1-6 alkyl group is selected from methyl, ethyl, propyl, butyl, pentyl or hexyl; further preferably, the C 1-6 alkyl group is a methyl group.
  • the R 1 and R 2 form a cyclic structure.
  • the 1,8-naphthyridine compound has the following structure:
  • the base is one or more of sodium carbonate, sodium hydroxide, sodium hydride, sodium methoxide, potassium tert-butoxide, sodium tert-butoxide and triethylamine.
  • the alcohol is one or more of methanol, ethanol, phenethyl alcohol and benzyl alcohol.
  • the methylating reagent is dimethyl sulfoxide.
  • the ratio of the mole (mol) of the 1,8-naphthyridine compound, the base, and the alcohol to the volume (L) of the methylating agent is 1:1-2:1:2.
  • the methylating reagent is dimethyl sulfoxide as an example.
  • the reactions involved in the above preparation method are as follows:
  • reaction mechanism of the present invention is as follows:
  • 1,8-naphthyridine compounds generate free radicals in the ortho position under the action of alkali and alcohol; similarly, dimethyl sulfoxide is used as a methylating agent to generate methyl free radicals under the same environment ,
  • the free radicals generated by the two are free radically coupled to form 2-methyl-1,8-naphthyridine compounds.
  • the present invention controls appropriate reaction conditions, prompts the reactants to effectively generate free radicals and react, and the adopted raw materials are cheap, safe and non-toxic, and have high reaction efficiency.
  • the crude product is purified after the completion of the reaction; the purification is column chromatography purification.
  • the eluent of the column chromatography purification is a mixed solution of petroleum ether: dichloromethane: ethyl acetate in a volume ratio of 0.5-50:0-20:1.
  • the above-mentioned preparation method of 2-methyl-1,8-naphthyridine compound includes the following steps:
  • reaction vessel mix the 1,8-naphthyridine compound of the corresponding structure, the base, the alcohol, and the methylating reagent, and react at 80-160°C for 5-24 hours. After the reaction, cool to room temperature, filter, The unreacted substance was removed by rotary evaporation under reduced pressure to obtain the crude product, and the crude product was purified by column chromatography to obtain 2-methyl-1,8-naphthyridine compounds.
  • the application of the 2-methyl-1,8-naphthyridine compound is an application in a reagent or medicine against human cancer K562 cells, HL-60 cells, HeLa cells, and BGC-823 cells.
  • the present invention improves the biological activity of 1,8-naphthyridines by introducing methyl functional groups into 1,8-naphthyridines, so that the obtained 2-methyl-1,8-naphthyridines
  • the compound has a novel structure and has anti-tumor activity.
  • the preparation method of the present invention does not require the addition of a metal catalyst, has mild conditions, is environmentally friendly, has high efficiency, simple and safe operation, non-toxic raw materials, and is cheap and easy to obtain; the compound of the present invention has good selectivity during the preparation process, and uses atoms High rate, simple side reaction, high yield of main reaction, it provides an economical, simple and effective preparation method for methylation of 1,8-naphthyridine compounds; the obtained diazacyclo product has a novel structure and can be further developed. Biological activity.
  • the present invention obtains a novel structure and biologically active diaza heterocycle compound through an efficient and simple preparation method, which not only brings economic benefits, but also conforms to the concept of green chemistry , To provide new ideas for the synthesis of diaza heterocycles.
  • the 2-methyl-1,8-naphthyridine compounds of the present invention have inhibitory effects on human cancer K562 cells, HL-60 cells, HeLa cells, and BGC-823 cells. Therefore, these compounds can be used as antitumor
  • the reagent is used in in vitro anti-tumor activity screening, and has certain potential application value in anti-tumor cell medicine.
  • Figure 1a and Figure 1b are the hydrogen spectrum and carbon spectrum of the compound 2a obtained in Example 1, respectively;
  • 3a and 3b are the hydrogen spectrum and carbon spectrum of compound 2c obtained in Example 3, respectively;
  • 4a and 4b are the hydrogen spectrum and carbon spectrum of the compound 2d obtained in Example 4, respectively;
  • 5a and 5b are the hydrogen spectrum and carbon spectrum of compound 2e obtained in Example 5, respectively;
  • 6a and 6b are the hydrogen spectrum and carbon spectrum of compound 2f obtained in Example 6, respectively;
  • Fig. 7a and Fig. 7b are the hydrogen spectrum and the carbon spectrum of the compound 2g obtained in Example 7, respectively;
  • 8a and 8b are the hydrogen spectrum and the carbon spectrum of the compound 2h obtained in Example 8 respectively;
  • 9a and 9b are the hydrogen spectrum and carbon spectrum of compound 2i obtained in Example 9 respectively;
  • 10a and 10b are the hydrogen spectrum and carbon spectrum of the compound 2j obtained in Example 10, respectively.
  • 2-Methyl-7-phenyl-1,8-naphthyridine has the following structure:
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2a was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 15 H 13 N 2 [M+H] + theoretical value (Calcd): 221.1073; actual measured value (found): 221.1064.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2b was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 16 H 15 N 2 O[M+H] + theoretical value (Calcd): 251.1179; actual measured value (found) : 251.1169.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • 2-(7-methyl-1,8-naphthyridin-2-yl)thiazole has the following structure:
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2c was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 12 H 10 N 3 S[M+H] + theoretical value (Calcd): 228.0590; actual measured value (found) : 228.0582.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • 2-Methyl-7-(pyrazin-2-yl)-1,8-naphthyridine has the following structure:
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2d was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 13 H 11 N 4 [M+H] + theoretical value (Calcd): 223.0978; actual measured value (found): 223.0971.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2e was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 17 H 15 N 2 [M+H] + theoretical value (Calcd): 247.1230; actual measured value (found): 247.1219.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • 2-Methyl-7-(4-trifluoromethylphenyl)-1,8-naphthyridine has the following structural formula:
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2f was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 16 H 12 F 3 N 2 [M+H] + theoretical value (Calcd): 289.0947; actual measured value (found ): 289.0935.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2g was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 13 H 11 N 2 O[M+H] + theoretical value (Calcd): 211.0866; actual measured value (found) : 211.0859.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • the reaction route is as follows:
  • the 2h molecular weight of the obtained compound was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 17 H 13 N 2 S[M+H] + theoretical value (Calcd): 277.0794; actual measured value (found) : 277.0788.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • 2-(1,3-Benzodioxy-5-yl)-7-methyl-1,8-naphthyridine has the following structure:
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2i was determined by electrospray ionization (ESI) high-resolution mass spectrometry (HRMS): C 16 H 13 N 2 O 2 [M+H] + theoretical value (Calcd): 265.0972; actual measured value (found ): 265.0961.
  • ESI electrospray ionization
  • HRMS high-resolution mass spectrometry
  • 2-(4-Bromophenyl)-3,7-dimethyl-1,8-naphthyridine has the following structure:
  • the reaction route is as follows:
  • the molecular weight of the obtained compound 2j was determined by electrospray ionization (ESI) high resolution mass spectrometry (HRMS): C 16 H 14 BrN 2 [M+H] + theoretical value (Calcd): 313.0335; actual measured value (found): 313.0335.
  • ESI electrospray ionization
  • HRMS high resolution mass spectrometry
  • the anti-tumor cell activity test was performed on the products obtained in Examples 1-10.
  • each compound is formulated into 100 ⁇ g ⁇ mL -1 methanol solution, and the positive control drugs 5-fluorouracil (5-FU) and docetaxol (docetaxol) are respectively formulated into 100 ⁇ g ⁇ mL -1 dimethyl Sulfoxide (DMSO) solution, methanol and DMSO solvents were used as blank controls, and MTT method was used to test the inhibitory effects of each compound on K562 cells, HL-60 cells, HeLa cells, and BGC-823 cells.
  • 5-fluorouracil 5-FU
  • docetaxol docetaxol
  • DMSO dimethyl Sulfoxide
  • MTT solution preparation 50mg of MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide) powder was dissolved in 10mL of PBS solution, and filtered with 0.22 ⁇ m Membrane filtration and storage in a refrigerator at 4°C.
  • Anti-tumor cell activity test Take K562 cells, HL-60 cells, HeLa cells, and BGC-823 cells in the logarithmic phase respectively, and centrifuge them on a centrifuge at 4°C, 3000 rpm for 3 minutes, aspirate the supernatant, and add fresh Dilute the RPMI-1640 medium to a cell suspension of 1 ⁇ 10 5 cells/ml. Inoculate 200 ⁇ L per well in a 96-well plate, incubate in a cell incubator at 37°C and 5% CO 2 for 1 hour, add 2 ⁇ L of sample solution to each well, set 3 parallel wells for each sample, and set up two groups of three each. For the blank control of the well, culture for 24h under the same conditions after loading the sample.
  • the MTT method was used to test the proliferation inhibitory activity of compounds 2a-2j on four kinds of tumor cells. The results are shown in Table 1.
  • the 2-methyl-1,8-naphthyridine compounds prepared by the present invention have a certain inhibitory effect on K562 cells, HL-60 cells, HeLa cells, and BGC-823 cells, indicating that they have certain Anti-tumor cell activity has potential application value in anti-tumor cell drugs.
  • the inhibitory effects of compounds such as 2i and 2j on K562 cell proliferation are comparable to the existing drugs 5-fluorouracil and docetaxel.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及合成技术领域，特别涉及2-甲基-1,8-萘啶类化合物，还涉及其制备方法与应用。本发明的2-甲基-1,8-萘啶类化合物具有式Ⅰ所示的结构；其中，R1选自苯基、取代苯基、噻唑基、吡嗪基、呋喃基、苯并噻吩基和1,3-苯并二氧基组成的组，R2为氢或烷基；或R1和R2相连成环状结构；所述取代苯基为硝基苯基、卤代苯基、甲氧基苯基或三氟甲基苯基；所述烷基为C1-6烷基。本发明的2-甲基-1,8-萘啶类化合物结构新颖，具有高的生物活性，在抗肿瘤药物的应用上具有一定的潜力；制备中不需要添加金属催化剂，条件温和、绿色环保、效率高、操作简单安全。

Description

2-甲基-1,8-萘啶类化合物及其制备方法与应用 技术领域
本发明涉及合成技术领域，特别涉及2-甲基-1,8-萘啶类化合物，还涉及其制备方法与应用。
背景技术
近年来，含氮的杂环化合物在现代药物研发中具有至关重要的作用，发展高效的含氮杂环化合物的构建方法也吸引了越来越多的关注。萘啶氮杂环化合物是一类非常重要的杂环体系，常见于药物中间体、天然产物中，具有潜在的生物活性。其中，1,8-萘啶也是一种重要的杂环体系，在有机中间体、医药、农药、材料科学等领域都有广泛的应用。
随着有机化学以及材料、医药等交叉学科的发展，科学家们从含氮杂环化合物中发现了大量新颖的药物和功能材料。据相关报道，在含氮杂环化合物的结构与功能的对应关系中，甲基化的影响是很有意义的。例如，DNA和RNA核碱基之间的区别仅在于一个甲基(即DNA的胸腺嘧啶和RNA的尿嘧啶)，而尿嘧啶甲基化成胸腺嘧啶可以调节许多生物过程。此外，在20种天然氨基酸中，甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸的生物活性受甲基数量和位置变化的调节，这意味着甲基在生物功能微调中的意义重大。
除了这些生物学作用外，近年来，在药物化学和制药工业中也认识到在候选药物中甲基化所带来的益处，而这被人们称之为“神奇的甲基化作用”。甲基化候选药物由于溶解度、构象和代谢活性的变化而表现出独特的性质。例如，p38a作为MAP3激酶的抑制剂，甲基化后p38a的效力显著增强，IC50由原来的大于2500nm变为约12nm。然而，对于2-甲基-1,8-萘啶的合成，大多数的方法仍需要采用金属催化，并且需要在高温条件下实现反应，具有原子利用率不高、副反应复杂、主反应收率不高等缺点。因此我们希望通过一种无金属催化、室温下的、绿色的、高效的、操作简单的甲基化策略来合成2-甲基-1,8-萘啶类化合物。
发明内容
针对现有技术的不足，本发明的目的在于提供一种2-甲基-1,8-萘啶类化合物及其制备方法与应用。本发明的2-甲基-1,8-萘啶类化合物结构新颖，具有高的生物活性。本发明的制备方法不需要添加金属催化剂，条件温和、绿色环保、效率高、操作简单安全，所制备的2-甲基-1,8-萘啶类化合物可进一步应用于抗肿瘤药物。
本发明采用以下技术方案：
2-甲基-1,8-萘啶类化合物，具有式Ⅰ所示的结构：
Figure PCTCN2020089428-appb-000001
其中，R 1选自苯基、取代苯基、噻唑基、吡嗪基、呋喃基、苯并噻吩基和1,3-苯并二氧基组成的组，R 2为氢或烷基；或R 1和R 2形成环状结构；
所述取代苯基为硝基苯基、卤代苯基、甲氧基苯基或三氟甲基苯基；
所述烷基为C 1-6烷基。
优选地，所述硝基苯基选自2-硝基苯基、3-硝基苯基或4-硝基苯基；进一步优选地，所述硝基苯基为4-硝基苯基。
优选地，所述卤代苯基选自2-卤代苯基、3-卤代苯基或4-卤代苯基；其中，卤素选自氟、氯、溴或碘；进一步优选地，所述卤代苯基为4-溴代苯基。
优选地，所述甲氧基苯基选自2-甲氧基苯基、3-甲氧基苯基或4-甲氧基苯基；进一步优选地，所述甲氧基苯基为3-甲氧基苯基。
优选地，所述噻唑基选自噻唑-2-基、噻唑-4-基或噻唑-5-基；进一步优选地，所述噻唑基为噻唑-2-基。
优选地，所述吡嗪基选自吡嗪-2-基。
优选地，所述三氟甲基苯基选自2-三氟甲基苯基、3-三氟甲基苯基或4-三氟甲基苯基；进一步优选地，所述三氟甲基苯基为4-三氟甲基苯基。
优选地，所述呋喃基选自呋喃-2-基或呋喃-3-基；进一步优选地，所述呋喃基为呋喃-2-基。
优选地，所述苯并噻吩基选自2-苯并噻吩基或3-苯并噻吩基；进一步优选地，所述苯并噻吩基为2-苯并噻吩基。
优选地，所述1,3-苯并二氧基选自1,3-苯并二氧-4-基或1,3-苯并二氧-5-基；进一步优选地，所述1,3-苯并二氧基为1,3-苯并二氧-5-基。
优选地，所述C 1-6烷基选自甲基、乙基、丙基、丁基、戊基或己基；进一步优选地，所述，所述C 1-6烷基为甲基。
优选地，所述R 1和R 2形成环状结构，具体地，2-甲基-1,8-萘啶类化合物具有如下结构：
Figure PCTCN2020089428-appb-000002
上述的2-甲基-1,8-萘啶类化合物的制备方法，包括以下步骤：
将1,8-萘啶类化合物、碱、醇、甲基化试剂混合均匀，在80-160℃下反应5-24小时，即得到2-甲基-1,8-萘啶类化合物。
优选地，反应在保护性气氛中进行；进一步优选地，反应在氮气气氛中进行。
优选地，所述1,8-萘啶类化合物具有式Ⅱ所示的结构：
Figure PCTCN2020089428-appb-000003
其中，其中，R 1选自苯基、取代苯基、噻唑基、吡嗪基、呋喃基、苯并噻吩基和1,3-苯并二氧基组成的组，R 2为氢或烷基；或R 1和R 2形成环状结构；
所述取代苯基为硝基苯基、卤代苯基、甲氧基苯基或三氟甲基苯基；
所述烷基为C 1-6烷基。
优选地，所述硝基苯基选自2-硝基苯基、3-硝基苯基或4-硝基苯基；进一步优选地，所述硝基苯基为4-硝基苯基。
优选地，所述卤代苯基选自2-卤代苯基、3-卤代苯基或4-卤代苯基；其中，卤素选自氟、氯、溴或碘；进一步优选地，所述卤代 苯基为4-溴代苯基。
优选地，所述甲氧基苯基选自2-甲氧基苯基、3-甲氧基苯基或4-甲氧基苯基；进一步优选地，所述甲氧基苯基为3-甲氧基苯基。
优选地，所述噻唑基选自噻唑-2-基、噻唑-4-基或噻唑-5-基；进一步优选地，所述噻唑基为噻唑-2-基。
优选地，所述吡嗪基选自吡嗪-2-基。
优选地，所述三氟甲基苯基选自2-三氟甲基苯基、3-三氟甲基苯基或4-三氟甲基苯基；进一步优选地，所述三氟甲基苯基为4-三氟甲基苯基。
优选地，所述呋喃基选自呋喃-2-基或呋喃-3-基；进一步优选地，所述呋喃基为呋喃-2-基。
优选地，所述苯并噻吩基选自2-苯并噻吩基或3-苯并噻吩基；进一步优选地，所述苯并噻吩基为2-苯并噻吩基。
优选地，所述1,3-苯并二氧基选自1,3-苯并二氧-4-基或1,3-苯并二氧-5-基；进一步优选地，所述1,3-苯并二氧基为1,3-苯并二氧-5-基。
优选地，所述C 1-6烷基选自甲基、乙基、丙基、丁基、戊基或己基；进一步优选地，所述，所述C 1-6烷基为甲基。
优选地，所述R 1和R 2形成环状结构，具体地，所述1,8-萘啶类化合物具有如下结构：
Figure PCTCN2020089428-appb-000004
优选地，所述碱为碳酸钠、氢氧化钠、氢化钠、甲醇钠、叔丁醇钾、叔丁醇钠和三乙胺中的一种或多种。
所述醇为甲醇、乙醇、苯乙醇和苯甲醇中的一种或多种。
优选地，所述甲基化试剂为二甲基亚砜。
优选地，所述1,8-萘啶类化合物、碱、醇的摩尔(mol)与甲基化试剂的体积(L)的比例为1：1-2：1：2。
甲基化试剂以二甲基亚砜为例，上述制备方法涉及的反应如下：
Figure PCTCN2020089428-appb-000005
具体地，本发明的反应机理如下：
Figure PCTCN2020089428-appb-000006
在本发明中，1,8-萘啶类化合物在碱、醇作用下，邻位产生自由基；同样地，二甲基亚砜作为甲基化试剂，在同样的环境下产生 甲基自由基，两者产生的自由基发生自由基偶联，形成2-甲基-1,8-萘啶类化合物。本发明控制适当的反应条件，促使反应物有效产生自由基并进行反应，所采用的原料低廉、安全无毒、反应效率高。
优选地，所述反应结束后对粗产物进行提纯；所述提纯为柱层析提纯。
进一步优选地，所述柱层析提纯的洗脱液为石油醚：二氯甲烷：乙酸乙酯的体积比为0.5-50：0-20：1的混合溶液。
具体地，上述的2-甲基-1,8-萘啶类化合物的制备方法，包括以下步骤：
在反应容器中，将相应结构的1,8-萘啶类化合物、碱、醇、甲基化试剂混合均匀，在80-160℃下反应5-24小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯得到2-甲基-1,8-萘啶类化合物。
上述的2-甲基-1,8-萘啶类化合物在制备抗肿瘤细胞药物中的应用。
优选地，所述的2-甲基-1,8-萘啶类化合物的应用，在抗人癌K562细胞、HL-60细胞、HeLa细胞、BGC-823细胞的试剂或药物中的应用。
本发明的有益效果：
(1)本发明通过在1,8-萘啶类化合物中引入甲基官能团，提高了1,8-萘啶类化合物的生物活性，使得到的2-甲基-1,8-萘啶类化合物具有新颖的结构并且具有抗肿瘤活性。
(2)本发明的制备方法不需要添加金属催化剂，条件温和、绿色环保、效率高、操作简单安全、原料无毒且价廉易得；本发明的化合物在制备过程中选择性好，原子利用率高、副反应简单、主反应收率高，为1,8-萘啶类化合物的甲基化提供一种经济简单的有效制备方法；得到的双氮杂环产物结构新颖，可进一步开发其生物活性。
(3)在复杂的双氮杂环的合成中，本发明通过高效简单的制备方法即得到结构新颖且具有生物活性的双氮杂环化合物，带来经济效益的同时，也符合绿色化学的理念，为双氮杂环的合成提供新思路。
(4)本发明的2-甲基-1,8-萘啶类化合物对人癌K562细胞、HL-60细胞、HeLa细胞、BGC-823细胞具有抑制作用，因此，该类化合物可作为抗肿瘤试剂用于体外抗肿瘤活性筛选中，在抗肿瘤细胞药物中具有一定的潜在应用价值。
附图说明
图1a和图1b分别为实施例1所得化合物2a的氢谱图和碳谱图；
图2a和图2b分别为实施例2所得化合物2b的氢谱图和碳谱图；
图3a和图3b分别为实施例3所得化合物2c的氢谱图和碳谱图；
图4a和图4b分别为实施例4所得化合物2d的氢谱图和碳谱图；
图5a和图5b分别为实施例5所得化合物2e的氢谱图和碳谱图；
图6a和图6b分别为实施例6所得化合物2f的氢谱图和碳谱图；
图7a和图7b分别为实施例7所得化合物2g的氢谱图和碳谱图；
图8a和图8b分别为实施例8所得化合物2h的氢谱图和碳谱图；
图9a和图9b分别为实施例9所得化合物2i的氢谱图和碳谱图；
图10a和图10b分别为实施例10所得化合物2j的氢谱图和碳谱图。
具体实施方式
下面通过实施例详细说明本发明。
实施例1
2-甲基-7-苯基-1,8-萘啶具有如下结构：
Figure PCTCN2020089428-appb-000007
2-甲基-7-苯基-1,8-萘啶的制备方法如下：
在反应容器中，将2-苯基-1,8-萘啶(5mmol,1g)、叔丁醇钾(10mmol,1.1g)、甲醇(5mmol,0.02g)、二甲基亚砜(10mL)混合均匀，在80℃下反应24小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-甲基-7-苯基-1,8-萘啶，即化合物2a。化合物2a为白色固体，熔点(m.p.)：108.9-109.7℃。
反应路线如下：
Figure PCTCN2020089428-appb-000008
所得化合物2a的氢谱图和碳谱图分别如图1a和图1b所示，结构表征数据如下：
1H NMR(400MHz,CDCl 3)δ8.35-8.30(m,2H),8.17(dd,J＝8.4,3.0Hz,1H),8.05(dd,J＝8.2,2.9Hz,1H),7.93(dd,J＝8.4,2.9Hz,1H),7.56-7.46(m,3H),7.33(dd,J＝8.2,2.5Hz,1H),2.83(s,3H)；
13C NMR(101MHz,CDCl 3)δ163.3,160.0,155.9,138.7,137.4,136.6,129.9,128.7,127.9,122.6,119.7,118.8,25.7。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2a的分子量：C 15H 13N 2[M+H] +的理论值(Calcd)：221.1073；实际测得值(found)：221.1064。
实施例2
2-(3-甲氧基苯基)-7-甲基1,8-萘啶，具有如下结构：
Figure PCTCN2020089428-appb-000009
2-(3-甲氧基苯基)-7-甲基1,8-萘啶的制备方法如下：
在反应容器中，将2-(3-甲氧基苯基)-1,8-萘啶(5mmol,1.2g)、叔丁醇钾(10mmol,1.1g)、乙醇(5mmol,0.02g)、二甲基亚砜(10mL)混合均匀，在160℃下反应5小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过 柱层析提纯即得到2-(3-甲氧基苯基)-7-甲基1,8-萘啶，即化合物2b，化合物2b为白色固体，熔点(m.p.)：136.2-137.9℃。
反应路线如下：
Figure PCTCN2020089428-appb-000010
所得化合物2b的氢谱图和碳谱图分别如图2a和图2b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.13(d,J＝8.4Hz,1H),8.02(d,J＝8.2Hz,1H),7.96-7.91(m,1H),7.89(d,J＝8.4Hz,1H),7.79(d,J＝7.7Hz,1H),7.39(t,J＝7.9Hz,1H),7.31(d,J＝8.2Hz,1H),7.01(dd,J＝8.2,2.6Hz,1H),3.91(s,3H),2.81(s,3H)；
13C NMR(126MHz,CDCl 3)δ163.3,160.1,159.8,155.7,140.1,137.4,136.7,129.6,122.7,120.3,119.8,119.1,116.5,112.6,55.6,25.7。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2b的分子量：C 16H 15N 2O[M+H] +的理论值(Calcd)：251.1179；实际测得值(found)：251.1169。
实施例3
2-(7-甲基-1,8-萘啶-2-基)噻唑，具有如下结构：
Figure PCTCN2020089428-appb-000011
2-(7-甲基-1,8-萘啶-2-基)噻唑的制备方法如下：
在反应容器中，将2-(1,8-萘啶-2-基)噻唑(5mmol,1.1g)、叔丁醇钾(10mmol,1.1g)、苯乙醇(5mmol,0.6g)、二甲基亚砜(10mL)混合均匀，在100℃下反应8小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-(7-甲基-1,8-萘啶-2-基)噻唑，即化合物2c。化合物2c为棕色固体，熔点(m.p.)：123.4-125.1℃；
反应路线如下：
Figure PCTCN2020089428-appb-000012
所得化合物2c的氢谱图和碳谱图分别如图3a和图3b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.41-8.33(m,1H),8.21(dd,J＝9.6,5.5Hz,1H),8.10-8.03(m,1H),7.97(d,J＝1.8Hz,1H),7.53(dd,J＝3.6,2.6Hz,1H),7.38-7.29(m,1H),2.81(s,3H)；
13C NMR(126MHz,CDCl 3)δ169.0,163.9,155.4,154.0,144.2,137.9,136.8,123.4,123.2,121.4,118.1,25.7。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2c的分子量：C 12H 10N 3S[M+H] +的理论值(Calcd)：228.0590；实际 测得值(found)：228.0582。
实施例4
2-甲基-7-(吡嗪-2-基)-1,8-萘啶，具有如下结构：
Figure PCTCN2020089428-appb-000013
2-甲基-7-(吡嗪-2-基)-1,8-萘啶的制备方法如下：
在反应容器中，将2-(吡嗪-2-基)-1,8-萘啶(5mmol,1g)、叔丁醇钾(10mmol,1.1g)、苯乙醇(5mmol,0.6g)、二甲基亚砜(10mL)混合均匀，在120℃下反应12小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-甲基-7-(吡嗪-2-基)-1,8-萘啶，即化合物2d。化合物2d为黄色油状(37.3毫克，56％产率)。
反应路线如下：
Figure PCTCN2020089428-appb-000014
所得化合物2d的氢谱图和碳谱图分别如图4a和图4b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ10.03(t,J＝3.7Hz,1H),8.65-8.58(m,2H),8.54(d,J＝8.4Hz,1H),8.25(d,J＝8.4Hz,1H),8.08(d,J＝8.3Hz,1H),7.37(d,J＝8.2Hz,1H),2.83(d,J＝8.6Hz,3H)；
13C NMR(126MHz,CDCl 3)δ163.9,157.1,155.4,150.5,145.1,144.6,143.4,137.9,136.8,123.6,121.2,119.1,25.8。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2d的分子量：C 13H 11N 4[M+H] +的理论值(Calcd)：223.0978；实际测得值(found)：223.0971。
实施例5
10-甲基-5,6-二氢萘酚[1,2-b][1,8]萘啶，具有如下结构：
Figure PCTCN2020089428-appb-000015
10-甲基-5,6-二氢萘酚[1,2-b][1,8]萘啶的制备方法如下：
在反应容器中，将5,6-二氢萘酚[1,2-b][1,8]萘啶(5mmol,1.2g)、叔丁醇钾(10mmol,1.1g)、苯乙醇(5mmol,0.5g)、二甲基亚砜(10mL)混合均匀，在110℃下反应14小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到10-甲基-5,6-二氢萘酚[1,2-b][1,8]萘啶，即化合物2e。化合物2e为棕色固体，熔点(m.p.)：140.4-141.7℃。
反应路线如下：
Figure PCTCN2020089428-appb-000016
所得化合物2e的氢谱图和碳谱图分别如图5a和图5b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.77(d,J＝7.5Hz,1H),7.94(s,1H),7.84(d,J＝9.2Hz,1H),7.38(dd,J＝14.0,6.7Hz,2H),7.30-7.24(m,2H),3.09(d,J＝5.3Hz,2H),2.98(d,J＝5.5Hz,2H),2.80(d,J＝4.9Hz,3H)；
13C NMR(126MHz,CDCl 3)δ162.1,156.1,155.3,139.4,136.1,134.4,134.2,130.9,130.3,127.9,127.3,127.1,122.4,120.2,28.4,28.2,25.6。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2e的分子量：C 17H 15N 2[M+H] +的理论值(Calcd)：247.1230；实际测得值(found)：247.1219。
实施例6
2-甲基-7-(4-三氟甲基苯基)-1,8-萘啶，具有如下结构式：
Figure PCTCN2020089428-appb-000017
2-甲基-7-(4-三氟甲基苯基)-1,8-萘啶的制备方法如下：
在反应容器中，将2-(4-三氟甲基苯基)-1,8-萘啶(5mmol,1.4g)、叔丁醇钾(10mmol,1.1g)、苯乙醇(5mmol,0.6g)、二甲基亚砜(10mL)混合均匀，在80℃下反应24小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-甲基-7-(4-三氟甲基苯基)-1,8-萘啶，即化合物2f。化合物2f为灰色固体，熔点(m.p.)：163.8-164.3℃。
反应路线如下：
Figure PCTCN2020089428-appb-000018
所得化合物2f的氢谱图和碳谱图分别如图6a和图6b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.40(d,J＝7.9Hz,2H),8.21(dd,J＝8.2,3.8Hz,1H),8.08(dd,J＝8.1,3.5Hz,1H),7.93(dd,J＝8.2,3.9Hz,1H),7.74(d,J＝8.1Hz,2H),7.37(dd,J＝8.2,3.0Hz,1H),2.84(s,3H)；
13C NMR(126MHz,CDCl 3)δ163.8,158.3,155.6,141.8,137.9,136.7,131.52(d,J＝32.4Hz),128.1,125.63(q,J＝3.1Hz),125.2,123.2,120.1,118.8,25.7；
19F NMR(471MHz,CDCl 3)δ-62.6。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2f的分子量：C 16H 12F 3N 2[M+H] +的理论值(Calcd)：289.0947；实际测得值(found)：289.0935。
实施例7
2-(呋喃-2-基)-7-甲基-1,8-萘啶，具有如下结构式：
Figure PCTCN2020089428-appb-000019
2-(呋喃-2-基)-7-甲基-1,8-萘啶的制备方法如下：
在反应容器中，将2-(呋喃-2-基)-1,8-萘啶(5mmol,1.0g)、叔丁醇钾(10mmol,1.1g)、苯乙醇(5mmol,0.6g)、二甲基亚砜(10mL)混合均匀，在80℃下反应24小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-(呋喃-2-基)-7-甲基-1,8-萘啶，即化合物2g。化合物2g为黄色固体，熔点(m.p.)：123.4-125.1℃。
反应路线如下：
Figure PCTCN2020089428-appb-000020
所得化合物2g的氢谱图和碳谱图分别如图7a和图7b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.10(dd,J＝8.3,6.1Hz,1H),7.98(dd,J＝8.1,6.0Hz,1H),7.88(dd,J＝8.3,6.1Hz,1H),7.69-7.57(m,1H),7.51(dd,J＝3.1,2.6Hz,1H),7.27(dd,J＝7.5,4.7Hz,1H),6.59(td,J＝3.3,1.7Hz,1H),2.78(s,3H)；
13C NMR(126MHz,CDCl 3)δ163.4,155.7,153.6,151.9,144.2,137.4,136.6,122.4,119.6,117.3,112.8,111.5,25.6。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2g的分子量：C 13H 11N 2O[M+H] +的理论值(Calcd)：211.0866；实际测得值(found)：211.0859。
实施例8
2-(苯并噻吩-2-基)-7-甲基-1,8-萘啶，具有如下结构：
Figure PCTCN2020089428-appb-000021
2-(苯并噻吩-2-基)-7-甲基-1,8-萘啶的制备方法如下：
在反应容器中，将2-(苯并噻吩-2-基)-1,8-萘啶(5mmol,1.3g)、甲醇钠(5mmol,0.5g)、苯甲醇(5mmol,0.5g)、二甲基亚砜(10mL)混合均匀，在150℃下反应18小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-苯并噻吩基-7-甲基-1,8-萘啶，即化合物2h。化合物2h为黄色固体，熔点(m.p.)：210.6-212.7℃。
反应路线如下：
Figure PCTCN2020089428-appb-000022
所得化合物2h的氢谱图和碳谱图分别如图8a和图8b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.12(d,J＝8.4Hz,1H),8.06(s,1H),8.01(d,J＝8.2Hz,1H),7.91(t,J＝7.4Hz,2H),7.86-7.78(m,1H),7.40-7.34(m,2H),7.32(d,J＝8.2Hz,1H),2.83(s,3H)；
13C NMR(126MHz,CDCl 3)δ163.7,155.7,155.3,144.7,141.6,140.3,137.3,136.6,125.6,124.5,124.5,123.7,122.8,122.8,120.1,118.2,77.3,77.1,76.8,25.7。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2h的分子量：C 17H 13N 2S[M+H] +的理论值(Calcd)：277.0794；实际测得值(found)：277.0788。
实施例9
2-(1,3-苯并二氧-5-基)-7-甲基-1,8-萘啶，具有如下结构：
Figure PCTCN2020089428-appb-000023
2-(1,3-苯并二氧-5-基)-7-甲基-1,8-萘啶的制备方法如下：
在反应容器中，将2-(1,3-苯并二氧-5-基)-1,8-萘啶(5mmol,1.5g)、氢氧化钠(10mmol,0.4g)、苯甲醇(5mmol,0.5g)、二甲基亚砜(10mL)混合均匀，在160℃下反应16小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-(1,3-苯并二氧-5-基)-7-甲基-1,8-萘啶，即化合物2i。化合物2i为黄色固体，熔点(m.p.)：182.2-183.5℃。
反应路线如下：
Figure PCTCN2020089428-appb-000024
所得化合物2i的氢谱图和碳谱图分别如图9a和图9b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ8.13(d,J＝8.5Hz,1H),8.03(d,J＝8.2Hz,1H),7.94(d,J＝1.8Hz,1H),7.85(d,J＝8.5Hz,1H),7.80(dd,J＝8.2,1.8Hz,1H),7.32(d,J＝8.2Hz,1H),6.93(d,J＝8.2Hz,1H),6.05(s,2H),2.83(s,3H)；
13C NMR(126MHz,CDCl 3)δ163.28,159.29,155.81,149.37,148.41,137.27,136.54,133.09,122.41,122.27,119.43,118.44,108.32,108.22,101.50,25.72。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2i的分子量：C 16H 13N 2O 2[M+H] +的理论值(Calcd)：265.0972；实际测得值(found)：265.0961。
实施例10
2-(4-溴苯基)-3,7-二甲基-1,8-萘啶，具有如下结构：
Figure PCTCN2020089428-appb-000025
2-(4-溴苯基)-3,7-二甲基-1,8-萘啶的制备方法如下：
在反应容器中，将2-(4-溴苯基)-3-甲基-1,8-萘啶(5mmol,1.5g)、叔丁醇钾(5mmol,1.1g)、乙醇(5mmol,0.02g)、二甲基亚砜(10mL)混合均匀，在140℃下反应24小时，反应结束后冷却至室温，过滤、减压旋蒸除去未反应物即得到粗产物，粗产物经过柱层析提纯即得到2-(4-溴苯基)-3,7-二甲基-1,8-萘啶，即化合物2j。化合物2j为灰色固体，熔点(m.p.)：158.0-160.7℃。
反应路线如下：
Figure PCTCN2020089428-appb-000026
所得化合物2j的氢谱图和碳谱图分别如图10a和图10b所示，结构表征数据如下：
1H NMR(500MHz,CDCl 3)δ7.99(d,J＝8.3Hz,1H),7.96(d,J＝3.4Hz,1H),7.57(d,J＝2.9Hz,4H),7.31(d,J＝8.2Hz,1H),2.77(s,3H),2.48(s,3H)；
13C NMR(126MHz,CDCl 3)δ162.6,161.6,154.3,139.0,137.8,135.9,131.2,131.1,129.4,123.1,122.9,119.9,25.6,20.5。
通过电喷雾电离(ESI)的高分辨质谱(HRMS)测定所得化合物2j的分子量：C 16H 14BrN 2[M+H] +的理论值(Calcd)：313.0335；实际测得值(found)：313.0335。
实验例
对实施例1-10所得产物进行抗肿瘤细胞活性测试。
(1)测试方法：将各化合物配制成100μg·mL -1的甲醇溶液，阳性对照药5-氟尿嘧啶(5-FU)和多烯紫杉醇(docetaxol)分别配成100μg·mL -1的二甲基亚砜(DMSO)溶液，分别以甲醇和DMSO溶剂为空白对照，采用MTT法测试各化合物对K562细胞、HL-60细胞、HeLa细胞、BGC-823细胞的抑制作用。
(2)细胞培养液的配制：将一袋RPMI-1640培养基粉末(Net wt 10.4g)倒入干净的烧杯中，用900mL超净水将其溶解，并加入100mg·mL -1的链霉素1mL、青霉素0.5mL及NaHCO 3 2g。磁力搅拌均匀后，于超净台中用已高压灭菌的蔡氏(Zeiss)滤器经0.22μm滤膜过滤除菌，滤液直接保存于湿热灭菌后的玻璃瓶中(450mL/瓶)。培养基使用前，取冷冻保藏的血清，56℃灭活30min后，加入已配好RPMI-1640培养液中(450mL培养基中加入50mL血清)，轻轻摇匀后，加盖，用锡箔纸封口，于4℃冰箱中保存。MTT溶液配制：50mg的MTT(3-(4，5-二甲基噻唑-2)-2，5-二苯基四氮唑溴盐)粉末溶解于10mL的PBS溶液中，用0.22μm的滤膜过滤，于4℃冰箱中保存。
(3)抗肿瘤细胞活性测试：分别取生长对数期的K562细胞、HL-60细胞、HeLa细胞、BGC-823细胞，于4℃、3000rpm离心机上离心3min，吸去上清液，加入新鲜的RPMI-1640培养基稀释成1×10 5个/毫升的细胞悬液。每孔200μL接种于96孔板中，于37℃、5％CO 2的细胞培养箱中培养1h后，每孔各加样品溶液2μL，每个样品设3个平行孔，另设两组各三孔的空白对照，加样后以相同条件培养24h。24h后，在光学显微镜下观察细胞有无形态变化，初步判断样品有无细胞毒活性，必要时进行拍照。每孔加入5mg·mL -1的MTT溶液各20μL，培养箱中继续培养4h。取出96孔板离心(4℃、2000rpm，20min)除去上清液，每孔各加150μL DMSO，充分振荡使紫色沉淀物完全溶解。在酶标仪上于570nm下测定其光密度OD值，每组样品取平均值并按IR％＝(OD 空白-OD 样品)/OD 空白×100％公式计算抑制率(IR％)。
利用MTT法测试化合物2a-2j对四种肿瘤细胞的增殖抑制活性，结果见表1。
表1化合物2a-2j对四种肿瘤细胞的增殖抑制活性的MTT法测试结果
Figure PCTCN2020089428-appb-000027
由表1可知，本发明制备的2-甲基-1,8-萘啶类化合物对K562细胞、HL-60细胞、HeLa细胞、BGC-823细胞具有一定的抑制作用，表明了其具有一定的抗肿瘤细胞活性，在抗肿瘤细胞药物中具有潜在应用价值。其中，化合物如2i、2j对K562细胞的增值抑制作用与现有药物5-氟尿嘧啶、多烯紫杉醇相当。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (10)

  1. 2-甲基-1,8-萘啶类化合物，具有式Ⅰ所示的结构：
    Figure PCTCN2020089428-appb-100001
    其中，R 1选自苯基、取代苯基、噻唑基、吡嗪基、呋喃基、苯并噻吩基和1,3-苯并二氧基组成的组，R 2为氢或烷基；或R 1和R 2形成环状结构；
    所述取代苯基为硝基苯基、卤代苯基、甲氧基苯基或三氟甲基苯基；
    所述烷基为C 1-6烷基。
  2. 权利要求1所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，包括以下步骤：
    将1,8-萘啶类化合物、碱、醇、甲基化试剂混合均匀，在80-160℃下反应5-24小时，即得到2-甲基-1,8-萘啶类化合物。
  3. 根据权利要求2所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，所述1,8-萘啶类化合物的具有式Ⅱ所示的结构：
    Figure PCTCN2020089428-appb-100002
    其中，R 1选自苯基、取代苯基、噻唑基、吡嗪基、呋喃基、苯并噻吩基和1,3-苯并二氧基组成的组，R 2为氢或烷基；或R 1和R 2形成环状结构；
    所述取代苯基为硝基苯基、卤代苯基、甲氧基苯基或三氟甲基苯基；
    所述烷基为C 1-6烷基。
  4. 根据权利要求2所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，所述碱为碳酸钠、氢氧化钠、氢化钠、甲醇钠、叔丁醇钾、叔丁醇钠和三乙胺中的一种或多种。
  5. 根据权利要求2所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，所述醇为甲醇、乙醇、苯乙醇和苯甲醇中的一种或多种。
  6. 根据权利要求2所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，所述甲基化试剂为二甲基亚砜。
  7. 根据权利要求2所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，所述1,8-萘啶类化合物、碱、醇的摩尔与甲基化试剂的体积的比例为1：1-2：1：2。
  8. 根据权利要求2所述的2-甲基-1,8-萘啶类化合物的制备方法，其特征在于，反应结束后对粗产物进行提纯；所述提纯为柱层析提纯。
  9. 权利要求1所述的2-甲基-1,8-萘啶类化合物在制备抗肿瘤细胞药物中的应用。
  10. 根据权利要求9所述的2-甲基-1,8-萘啶类化合物的应用，在抗人癌K562细胞、HL-60细胞、HeLa细胞、BGC-823细胞的试剂或药物中的应用。
PCT/CN2020/089428 2019-06-18 2020-05-09 2-甲基-1,8-萘啶类化合物及其制备方法与应用 WO2020253415A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910524507.XA CN110272417B (zh) 2019-06-18 2019-06-18 2-甲基-1,8-萘啶类化合物及其制备方法与应用
CN201910524507.X 2019-06-18

Publications (1)

Publication Number Publication Date
WO2020253415A1 true WO2020253415A1 (zh) 2020-12-24

Family

ID=67960910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/089428 WO2020253415A1 (zh) 2019-06-18 2020-05-09 2-甲基-1,8-萘啶类化合物及其制备方法与应用

Country Status (2)

Country Link
CN (1) CN110272417B (zh)
WO (1) WO2020253415A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272417B (zh) * 2019-06-18 2021-07-13 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105111208A (zh) * 2015-09-22 2015-12-02 中国科学院化学研究所 一种四氢化1,8-萘啶类化合物的制备方法及其制得的手性产品
CN109678796A (zh) * 2017-10-19 2019-04-26 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN110272417A (zh) * 2019-06-18 2019-09-24 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
NZ526450A (en) * 2000-12-21 2005-04-29 Pliva Istrazivacki Inst D Macrolide antibiotics
TW201628622A (zh) * 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105111208A (zh) * 2015-09-22 2015-12-02 中国科学院化学研究所 一种四氢化1,8-萘啶类化合物的制备方法及其制得的手性产品
CN109678796A (zh) * 2017-10-19 2019-04-26 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN110272417A (zh) * 2019-06-18 2019-09-24 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry 17 June 2007 (2007-06-17), ANONYMOUS: "Benzo[b][1,8]naphthyridine, 6,7,8,9-tetrahydro-2,8-dimethyl- (CA INDEX NAME)", XP055766209, retrieved from STN Database accession no. 937644-48-9 *
DEEPAK P SHELAR; SANDEEP R PATIL; RAMHARI V ROTE; RAGHUNATH B TOCHE; MADHUKAR N JACHAK: "Synthesis and Fluorescence Investigation of Differently Substituted Benzo[b][1, 8]Naphthyridines: Interaction with Different Solvents and Bovine Serum Albumin (BSA).", JOURNAL OF FLUORESCENCE, vol. 21, no. 3, 9 December 2010 (2010-12-09), pages 1033 - 1047, XP019919341, ISSN: 1573-4994, DOI: 10.1007/s10895-010-0783-1 *
GALATSIS; YAMAGATA P; WENDT K; CONNOLLY J A; MICKELSON C J; MILBANK J W; BOVE J B J; KNAUER S E; BROOKER C S; AUGELLI-SZAFRAN R M;: "Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 23, 2 November 2007 (2007-11-02), pages 6525 - 6528, XP022325929, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2007.09.083 *
SHAOHUA JIANG, YANG ZHIHAI, GUO ZIYIN, LI YIBIAO, CHEN LU, ZHU ZHONGZHI, CHEN XIUWEN: "Transition metal-free α-methylation of 1,8-naphthyridine derivatives using DMSO as methylation reagent", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 17, no. 31, 25 July 2019 (2019-07-25), pages 7416 - 7424, XP055766177, ISSN: 1477-0520, DOI: 10.1039/C9OB01490J *

Also Published As

Publication number Publication date
CN110272417B (zh) 2021-07-13
CN110272417A (zh) 2019-09-24

Similar Documents

Publication Publication Date Title
TWI787018B (zh) 轉染過程重排之抑制劑
FR3037959A1 (zh)
CN101657422A (zh) 过渡金属催化的n-氨基吲哚的合成
KR102580087B1 (ko) 자가포식 조절인자(autophagy regulator)로서 사용된 화합물, 및 이에 대한 제조 방법 및 이의 용도
Molina et al. Carbodiimide-Mediated Preparation of the Tricyclic Pyrido [3 ‘, 2 ‘: 4, 5] pyrrolo [1, 2-c] pyrimidine Ring System and Its Application to the Synthesis of the Potent Antitumoral Marine Alkaloid Variolin B and Analog
Wang et al. A Synthetic Protocol for the Construction of Chroman‐Spiroquinazolin (thi) one Framework via a Metal‐Free, Three‐Component, Domino, Double Annulations
WO2019144764A1 (zh) 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
Radia et al. Design and synthesis of novel 1, 3, 4‐oxadiazole based azaspirocycles catalyzed by NaI under mild condition and evaluated their antidiabetic and antibacterial activities
Ullah et al. Synthesis of an isoindoline-annulated, tricyclic sultam library via microwave-assisted, continuous-flow organic synthesis (MACOS)
WO2020253415A1 (zh) 2-甲基-1,8-萘啶类化合物及其制备方法与应用
CN108503623A (zh) 一种抑制prmt7的化合物及其制备方法与应用
Mao et al. Visible-Light-Mediated Tandem Difluoromethylation/Cyclization of Alkenyl Aldehydes toward CF2H-Substituted Chroman-4-one Derivatives
Zhu et al. One-pot three-component strategy for polysubstituted 2-aminothiazoles via ring opening of α-nitro epoxides
EP3383875B1 (en) 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
Xie et al. Design and organocatalytic synthesis of spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors
Xie et al. The application of tandem Aza‐Wittig reaction to synthesize artemisinin–guanidine hybrids and their anti‐tumor activity
CN109651333A (zh) 一种具有抗肿瘤活性的2-吲哚-3-基-喹啉类化合物及其制备方法和应用
Voznesenskaia et al. Pictet–Spengler Synthesis of Perfluoroalkylated Tetrahydro-γ-carbolines and Tetrahydropyrrolopyrazines
Tu et al. An efficient chemoselective synthesis of pyrido [2, 3-d] pyrimidine derivatives under microwave irradiation
CN113105459B (zh) 一种三唑并嘧啶衍生物及其制备方法和应用
CN111285792B (zh) 2-取代吲哚化合物及其制备方法
Butler et al. Desymmetrization Reactions of Indigo with Grignard Reagents for the Synthesis of Selective Antiplasmodial [1 H, 3′ H]-3-Aryl-2, 2′-diindol-3′-ones
Zhang et al. Discovery of [1, 2, 4] triazolo [4, 3-a] pyrazine derivatives bearing a 4-oxo-pyridazinone moiety as potential c-Met kinase inhibitors
CA2417629C (en) Derivatives of variolin b
Feng et al. Highly Efficient Synthesis of N-Sulfonylamidines via Silver-Catalyzed or Metal-Free Thermally Promoted Denitrogenative Amination of N-Sulfonyl-1, 2, 3-triazoles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20827756

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20827756

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13/05/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20827756

Country of ref document: EP

Kind code of ref document: A1